Annual report pursuant to Section 13 and 15(d)

Income Taxes (Details Narrative)

v3.23.1
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Mar. 19, 2018
Operating Loss Carryforwards [Line Items]      
Deferred tax assets, capital loss carryforwards $ 24,000,000.0 $ 12,500,000  
Net operating loss carryforwards $ 7,400,000    
Net operating loss carryforward, expiration date 2037    
Net operating loss carryforward term 20 years    
Income tax examination description Pursuant to Code Sec. 382 of the Internal Revenue Code (“the Code”), the utilization of our net operating loss carryforwards could be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. We have not completed a Sec. 382 study and as such our net operating loss carryforwards may be subject to such limitation.    
Deferred tax liability, intangible assets 2,145,620  
Income tax expense benefit 530,611  
Capitalized research and development costs 1,929,462  
Valuation allowance deferred tax asset 7,400,000 2,900,000  
penalties and interest expense 0 $ 0  
Research and Development Expense [Member]      
Operating Loss Carryforwards [Line Items]      
Capitalized research and development costs 7,200,000    
License Rights [Member] | CoNCERT Pharmaceuticals, Inc [Member]      
Operating Loss Carryforwards [Line Items]      
Deferred tax liabilities     $ 3,037,147
Deferred tax liability, intangible assets     11,038,929
Deferred tax liability, expenses     $ 1,782
Domestic Tax Authority [Member]      
Operating Loss Carryforwards [Line Items]      
Net operating loss carryforwards $ 23,700,000